Screener
Palvella Therapeutics PVLA Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Change in fair value of derivative liabilities – royalty agreement | 116 | 75 |
| Change in fair value of derivative liabilities – contingent value right liability | (202) | — |
| Stock-based compensation | 3,376 | 1,094 |
| Accretion on marketable securities | (15) | — |
| Non-cash lease operating expense | 44 | — |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (357) | 819 |
| Accounts payable | 851 | 1,124 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's accretion (amortization) of discounts and premiums, investments?
- Palvella Therapeutics (PVLA) reported accretion (amortization) of discounts and premiums, investments of $15K in Q1 2026.
Ask your AI about Palvella Therapeutics's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude